Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Actinium Pharmaceuticals (DE:7AY1)
FRANKFURT:7AY1
RESEARCH TOOLSreports
Holding DE:7AY1?
Track your performance easily
7AY1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.41 - €9.80
Previous Close€1.73
Volume0.00
Average Volume (3M)62.00
Market Cap
€52.84M
Enterprise Value-€26.22M
Total Cash (Recent Filing)$86.04M
Total Debt (Recent Filing)$1.85M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Mar 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding31,154,376
10 Day Avg. Volume0
30 Day Avg. Volume62
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.14
Price to Sales (P/S)692.32
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-323.69
Enterprise Value/Gross Profit-323.69
Enterprise Value/Ebitda0.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Actinium Pharmaceuticals News
PremiumCompany Announcements
Actinium Pharmaceuticals Strengthens Board with New Appointment
Bulls Say, Bears Say
Bulls Say
Innovative ManufacturingActinium Pharmaceuticals announced a multi-million-dollar investment in a strategic initiative to support the development and deployment of its cyclotron-based method of manufacturing high-purity alpha-emitting Actinium-225.
Pipeline And Financial StabilityActinium has over 2 years of cash and its pipeline, with an analyst maintaining a Buy rating.
Regulatory ProgressPartner Immedica has reported favorable conversations with regulatory agencies in Europe and is expected to file for approval.
Bears Say
Financial PerformanceDecreasing the terminal growth rate used in the risk-adjusted discounted cash flow analysis from 2% to -5% reflects potential headwinds and uncertainty following the deprioritization of Iomab-B development.
Regulatory ChallengesThe FDA determined that the P3 SIERRA trial was not sufficient to support a BLA filing, necessitating another trial with an overall survival endpoint.
Strategic DecisionsATNM does not plan to fund the late-stage Iomab-B trial now required for BLA filing and will instead search for amenable U.S. partners.
---
Options Prices
Currently, No data available
---
Ownership Overview
6.13%
Insiders
8.20% Mutual Funds
1.17% Other Institutional Investors
75.52% Public Companies and
Individual Investors
7AY1 FAQ
What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was €1.41 and its highest was €9.80 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Currently, no data Available
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s upcoming earnings report date is Mar 14, 2025 which is in 120 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Actinium Pharmaceuticals released its earnings results on Mar 15, 2024. The company reported -€0.322 earnings per share for the quarter, beating the consensus estimate of -€0.54 by €0.218.
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Overvalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actinium Pharmaceuticals have?
Actinium Pharmaceuticals has 31,195,890 shares outstanding.
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Actinium Pharmaceuticals reported an EPS of -€0.322 in its last earnings report, beating expectations of -€0.54. Following the earnings report the stock price went down -5.738%.
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Among the largest hedge funds holding Actinium Pharmaceuticals’s share is Royce & Associates LLC. It holds Actinium Pharmaceuticals’s shares valued at 370K.
---
Actinium Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.08%
12-Months-Change
Fundamentals
Return on Equity
-87.96%
Trailing 12-Months
Asset Growth
-9.28%
Trailing 12-Months
Company Description
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.
---
7AY1 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
ADC Therapeutics
―
Cellectar Biosciences
―
Cellectis SA
―
Advaxis
―
Actinium Pharmaceuticals
―
Best Analysts Covering 7AY1
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-45.69%
reiterated a buy rating 3 months ago
Copying Justin Walsh's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -45.69% per trade.
---